Does the use of mTOR inhibitors increase long-term mortality in kidney recipients?

American Journal of Transplantation

Volumn 12, Issue 2, 2012, Pages 277-278

  Bunnapradist, S ^a   Kalantar Zadeh, K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

CAUCASIAN; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE MARKER; DRUG FATALITY; EDITORIAL; FOLLOW UP; GRAFT RECIPIENT; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MORTALITY; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPENSITY SCORE;

FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE CARE; TOR SERINE-THREONINE KINASES;

EID: 84856464845     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03829.x     Document Type: Editorial

References (4)

1. Schold JD, Kaplan B,. Design and analysis of clinical trials in transplantation: Principles and pitfalls. Am J Transplant 2008; 8: 1779-1785.
2. Cortazar F, et al,. Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin. Am J Transplant 2011; doi:.
3. Lebranchu Y, Thierry A, Thervet E, et al,. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the postconcept study. Am J Transplant 2011; 11: 1665-1675.
4. Alberu J, Pascoe MD, Campistol JM, et al,. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011; 92: 303-310.